20th International Congress » Parkinson's disease: Clinical trials, pharmacology and treatment

Date: Thursday, June 23, 2016

Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Session Type: Poster Session

Meeting: 20th International Congress

12:00pm-1:30pm: A combined therapeutic approach in the management of abnormal postures in Parkinson’s disease

S. Di Martino, E. Unti, C. Tramonti, S. Mazzucchi, U. Bonuccelli, B. Rossi, R. Ceravolo, C. Chisari (Pisa, Italy)

12:00pm-1:30pm: A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced Parkinson’s disease: The INVEST study

D. van Poppelen, R.M.A. de Bie, J.M. Dijk (Amsterdam, Netherlands)

12:00pm-1:30pm: A national case study of virtual care visits for Parkinson’s disease (RACE-PD): Interim assessment of participant and investigator experiences

R. Korn, H.T. Keenan, T. Felong, S. Goldenthal, S. Kanchana, H. Schwarz, S. Sharma, K. Andrzejewski, E.A. Stevenson, R. Barbano, G. Kang, K. Rizer, A. Shukla, M.J. Dodge, C. Tanner, M. Katz, R. Rodriguez, N. Galifianakis, W. Zhu (Rochester, NY, USA)

12:00pm-1:30pm: A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Feasibility and safety

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm: A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Signal of efficacy

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm: A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

12:00pm-1:30pm: Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone

J. Ferreira, A. Lees, O. Rascol, T. Müller, A. Santos, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

12:00pm-1:30pm: Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease

H. Ito, T. Kamei (Fujisawa, Japan)

12:00pm-1:30pm: AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

12:00pm-1:30pm: Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany

D. Maessen, G. Ebersbach, L. Timmermann, A. Ceballos-Baumann (Düsseldorf, Germany)

12:00pm-1:30pm: Association of Parkinson’s disease with essential tremor

D. Aygun (Samsun, Turkey)

12:00pm-1:30pm: Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists

S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

12:00pm-1:30pm: Auditory cues during obstacle crossing increase gait asymmetry in neurologically health individuals but not in people with Parkinson’s disease

M.B. Pestana, L.T.B. Gobbi, L. Simieli, D. Orcioli-Silva, A.M. Baptista, V.S. Beretta, P.C.R. Santos, T. Penedo, V.I.A. Pereira, F.A. Barbieri (Rio Claro, Brazil)

12:00pm-1:30pm: Balance and gait disturbances in Parkinson’s disease patients with falls and freezing of gait

J. Stozek, M. Rudzinska, S. Bukowczan, A. Szczudlik (Cracow, Poland)

12:00pm-1:30pm: Balance training in individual’s with Parkinson’s disease: Therapist-supervised vs. home-based exercise programmes

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm: Best supportive care or palliative care for late stage Parkinsonian syndromes?

S. Lorenzl, C. Richinger, C. Schmotz, G. Nübling (Salzburg, Austria)

12:00pm-1:30pm: Biseptol a new antiParkinsonian agent?

K. Karpinska, V. Smolanka (Uzhgorod, Ukraine)

12:00pm-1:30pm: Blindfolded balance training in patients with Parkinson’s disease: A sensory-motor strategy to improve the gait

A. Peppe, S. Bonnì, M. Fabio, K. Giacomo, A. Martino Cinnera, M. Tramontano, C. Caltagirone (Rome, Italy)

12:00pm-1:30pm: Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm: Can hospital admissions predict mortality in Parkinson’s?

B. Mohamed, N. Leopold, C. Thomas (Cardiff, United Kingdom)

12:00pm-1:30pm: Can treadmill training facilitate the dual-task gait in Parkinson’s disease?

A.V.C. Sousa, L.M.M. Santiago, R.E.O. Silva, A.P. Spaniol, D.A. Oliveira, É.R.V.P. Galvão, T.S. Ribeiro, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm: Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm: Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease

T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, S. Lasch, C. Tanner, D. Jennings, K. Kieburtz, K. Marek, On behalf of the PPMI Investigators (Chicago, IL, USA)

12:00pm-1:30pm: Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm: Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

12:00pm-1:30pm: Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm: Contributions of sensorial feedback to gait in Parkinson’s disease

F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

12:00pm-1:30pm: Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

12:00pm-1:30pm: Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

12:00pm-1:30pm: Correlation between Parkinson’s disease and malignant tumors

E. Binaghi, M.M. Mascia, P. Solla, M. Meloni, R. Farris, D. Ciaccio, G. Orofino, F. Marrosu, A. Cannas (Cagliari, Italy)

12:00pm-1:30pm: Creatine for patients with Parkinson’s disease: A meta-analysis

A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

12:00pm-1:30pm: Creativity related to dopaminergic treatment. A multicenter study

P.J. Garcia Ruiz, J.C. Martinez Castrillo, L. Vela (Madrid, Spain)

12:00pm-1:30pm: Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

12:00pm-1:30pm: Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

12:00pm-1:30pm: Development of a nanoherbaceutical formulation containing compound extracts from huperzia serrata, mucuna pruriens and withania somnifera for the prevention and treatment of Parkinson’s disease

V. Kumar, P.C. Bhatt (Allahabad, India)

12:00pm-1:30pm: Diagnostic value of a new coronal examination plane in transcranial nigral sonography and of additional M-mode tremor frequency determination for the differentiation of idiopathic Parkinson’s disease and essential tremor

L. Tönges, R. Daniel, D. Woitalla, S. Muhlack, R. Gold, C. Krogias (Bochum, Germany)

12:00pm-1:30pm: Differential clinical outcomes in unifocal vs. multifocal premotor rTMS for Parkinson’s disease: A randomized trial

M.C. Biagioni, A.Y. Son, S. Agarwal, G. Dacpano, M. Brys, P. Kumar, A. Cucca, J. Singleton-Garvin, R. Gilbert, A. Quartarone, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm: Differential effects of tango, treadmill, and stretching interventions on gait in people with Parkinson’s disease

M.E. McNeely, R.P. Duncan, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm: DIRECT DBS: A prospective, multi-center clinical trial with blinding for a directional DBS lead

J. Volkmann, S. Chabardes, G.K. Steinke, S. Carcieri, N. Van Dyck (Wuerzberg, Germany)

12:00pm-1:30pm: Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

12:00pm-1:30pm: Diverse effects of alpha-synuclein fibrils on various neuron cell lines, using different buffers

F. Aliakbari, D. Morshedi, A.A. Shabani, H. Mohammad Beigi, A. Tayaranian Marvian, P. Shariati, S.A. Shojaosadati, A.A. Saboury (Semnan, Islamic Republic of Iran)

12:00pm-1:30pm: Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?

R.P. Duncan, M.E. McNeely, G.M. Earhart (Saint Louis, MO, USA)

12:00pm-1:30pm: Does physical exercise influence the cognitive domains that predict dementia in Parkinson’s disease?

C.R.A. Silveira, E.A. Roy, B.N. Intzandt, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm: Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

12:00pm-1:30pm: Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

12:00pm-1:30pm: Drug safety in the pharmacotherapy of Parkinson’s disease

S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

12:00pm-1:30pm: Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

12:00pm-1:30pm: Duodenal levodopa infusion: Safety and efficacy in a 6 years outpatient follow-up

S. Simoni, N. Tambasco, E. Sacchini, P. Nigro, F. Ripandelli, P. Calabresi (Perugia, Italy)

12:00pm-1:30pm: Duodopa treatment experience in Oradea

M. Sabau, L. Botnaru, A. Badea, C. Dudas (Oradea, Romania)

12:00pm-1:30pm: Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease

S. Luo, J. Wang (Houston, TX, USA)

12:00pm-1:30pm: Effect of over(exaggerated) articulation technique in voice and speech of individuals with Parkinson’s disease with deep brain stimulation

G.L.A. Diaféria, F.A.M. Bento, M. Padovani, E.T. Fonoff, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm: Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

12:00pm-1:30pm: Effectiveness of a multidisciplinary PD clinic in improving quality of life

H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:00pm-1:30pm: Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies

K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara (Tokyo, Japan)

12:00pm-1:30pm: Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease

C.L. Chung, M.K.Y. Mak (Hong Kong, Hong Kong)

12:00pm-1:30pm: Effects of exercise intervention on balance and gait performance, and balance confidence in people with Parkinson’s disease – A meta-analysis

M.K. Mak, I.S. Wong-Yu (Hong Kong, People's Republic of China)

12:00pm-1:30pm: Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

12:00pm-1:30pm: Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm: Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

12:00pm-1:30pm: Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease

S.R. Schreglmann, F. Büchele, M. Sommerauer, L. Epprecht, G. Kägi, S. Hägele-Link, O. Götze, L. Zimmerli, D. Waldvogel, C.R. Baumann (London, United Kingdom)

12:00pm-1:30pm: Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

12:00pm-1:30pm: Effects of videogame step training on gait adaptability in people with Parkinson´s disease – A randomized controlled trial

M.J.D. Caetano, J.C. Menant, C.G. Canning, J. Song, D. Schoene, M. Brodie, S.R. Lord (Sydney, Australia)

12:00pm-1:30pm: Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

12:00pm-1:30pm: Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm: Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation

N. Kanzato, K. Nakachi, T. Naka, M. Higa, S. Mochizuki, Y. Miyamae (Okinawa Prefecture, Haebaru-cho, Japan)

12:00pm-1:30pm: Eight weeks of home-based balance training not as effective as therapist-based during dual tasks

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm: Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease

F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm: Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

12:00pm-1:30pm: Establishment of InMotion, an independent, fee-free community center for persons with movement disorders

D.E. Riley, K.M. Jaffe, J.Z. Peters (Warrensville Heights, OH, USA)

12:00pm-1:30pm: Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension

S.H. Isaacson, S. Brillman, N. Chhabria (Boca Raton, FL, USA)

12:00pm-1:30pm: Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment

N. Lopes, J. Ferreira, A. Lees, T. Müller, H. Reichmann, H. Gama, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

12:00pm-1:30pm: Exercise-induced adaptive neuroplasticity in the MPTP mouse model of Parkinson’s disease

C.J.H.M. Klemann, G. Poelmans, G.J.M. Martens, J.E. Visser (Nijmegen, Netherlands)

12:00pm-1:30pm: Experience with utilization of rytary in the clinical setting

Y. Kianirad, T. Simuni, C. Zadikoff, D. Bega, M. Afshari, S. Jonnalagadda (Chicago, IL, USA)

12:00pm-1:30pm: Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:00pm-1:30pm: Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression

N. Lopes, J. Ferreira, A. Lees, W. Poewe, H. Reichmann, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm: Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease

A. Ashrafi, M. Buttini, P. Garcia, A. del Sol, E. Glaab (Esch-sur-Alzette, Luxembourg)

12:00pm-1:30pm: Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

12:00pm-1:30pm: Falls and frailty predicate escalating care needs in Parkinson’s disease

B. Mohamed, C. Thomas, H. Shukla, S. Aithal (Cardiff, United Kingdom)

12:00pm-1:30pm: Feasibility and preliminary efficacy of a telehealth approach to group tango instruction for people with Parkinson’s disease

K.J. Seidler, R.P. Duncan, M.E. McNeely, M.E. Hackney, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm: Feasibility of implementing a long-term mobile device program in PD patients

L.R. Bataille, L.D. Herron, M. Afek, I. Feldman, C. Admati, S. Chowdhury (New York, NY, USA)

12:00pm-1:30pm: Feasibility, safety and effects of a group intervention based on European physiotherapy guideline for Parkinson´s disease

J.E. Pompeu, T.B. Freitas, R.A. Nuvolini, K.G. Silva, F. Doná, R.A. Andreotti, N.A. Mazzini, M.G.R. Almeida, C. Torriani-Pasin (Sao Paulo, Brazil)

12:00pm-1:30pm: Fighting Freezing of gait in Parkinson’s disease: Effect of a phase-dependent tactile biofeedback

M. Mancini, K. Smulders, G. Harker, A.C. Fortaleza, J.G. Nutt, F.B. Horak (Portland, OR, USA)

12:00pm-1:30pm: Fox insight wear ecosystem: using mobile technology and cloud-based computing to support PD research

I. Feldman, M. Afek, L. Bataille (Gedera, Israel)

12:00pm-1:30pm: Group climate in the voice therapy of patients with Parkinson’s disease

G.L.A. Diaféria, P.B. Takaki, G. Madazio, C. Pacheco, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm: Healthcare burden of Parkinson’s disease

M. Tagliati, A.T. Connolly (Los Angeles, CA, USA)

12:00pm-1:30pm: Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature

R.W.K. Borgemeester, G.F.H. Diercks, M.L.A. Schuttelaar, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm: Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

12:00pm-1:30pm: Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

12:00pm-1:30pm: Improved motor functioning of people with Parkinson’s disease following dance intervention

S.M. Simone, K.A. Beben, S.E. Maguire, C. Noudga, K.L.M. Martin, G.N. Luabeya, P. Dhami, R.J. Bar, J.F. DeSouza (Toronto, ON, Canada)

12:00pm-1:30pm: Improvement in posture, pain, and cardiac autonomic function in a prospective study of osteopathic manipulative medicine and physical therapy for camptocormia in Parkinson’s disease

J.D. Mancini, D.M. Pasternack, N. Caruana, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm: Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients

M. Zibetti, S. Angrisano, F. Dematteis, A. Romagnolo, A. Merola, L. Lopiano (Torino, Italy)

12:00pm-1:30pm: Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease

B. Pouyatos, S.J. Perry, D.E. Grigoriadis, R. Maury, C. Bouyssières, C. Roucard, V. Duveau, Y. Roche (La Tronche, France)

12:00pm-1:30pm: Improving provision of Parkinson’s disease exercise classes

C. Carroll, P. Pujara, J. Rideout (Plymouth, United Kingdom)

12:00pm-1:30pm: Influence of treadmill gait training with additional load on motor function, postural instability and history of falls for individuals with Parkinson’s disease: A randomized clinical trial

L.C.L. Trigueiro, A.V.C. Sousa, G.L. Gama, T.S. Ribeiro, L.G.L.M. Ferreira, C.R. Simão, É.R.V.P. Galvão, E.M.G.S. Silva, C.G. Júnior, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm: Inhibition of glucosylceramide synthase reduces pathology and improves cognition in synucleinopathy murine models

L. Shihabuddin, C. Viel, J. Clarke, H. Park, J.C. Dodge, J. Marshall, B. Wang, S.H. Cheng, S.P. Sardi (Framingham, MA, USA)

12:00pm-1:30pm: Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

12:00pm-1:30pm: Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

12:00pm-1:30pm: Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

12:00pm-1:30pm: Medication use patterns vary across expert Parkinson’s disease clinics

P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

12:00pm-1:30pm: Medicinal cannabis for Parkinson’s disease: A survey of practices, beliefs, and attitudes among providers at NPF centers of excellence

D. Bega, T. Simuni, M.S. Okun, P. Schmidt (Chicago, IL, USA)

12:00pm-1:30pm: Minimizing levodopa titration period for Parkinson’s disease (PD)

I. Thomas, M. Alam, D. Nyholm, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm: Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease

M. Senek, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, A. Ericsson, S. Lycke, A. Medvedev, M. Memedi, F. Ohlsson, J. Spira, J. Westin, D. Nyholm (Uppsala, Sweden)

12:00pm-1:30pm: Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

12:00pm-1:30pm: Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm: ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump

R. Shaltiel-Karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas, A. Rubinski, Y.S. Schiffenbauer, A. Nyska, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm: New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)

12:00pm-1:30pm: Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm: Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

12:00pm-1:30pm: Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

12:00pm-1:30pm: Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)

12:00pm-1:30pm: Objective measurement in clinical care of patients with Parkinson’s disease

M. Horne, K. Kotschet, M. Braybrook (Parkville, Australia)

12:00pm-1:30pm: Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

12:00pm-1:30pm: Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)

12:00pm-1:30pm: Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies

A. Lees, J. Ferreira, H. Reichmann, E. Tolosa, A. Santos, C. Oliveira, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm: Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies

A. Lees, J. Ferreira, T. Müller, F. Stocchi, C. Oliveira, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm: Osteopathic manipulative treatment in Parkinson’s disease: Preliminary results of a double blind sham-controlled cross-over study

S. Varanese, L. Cicchitti, G. Travaglini, V. Carafa, N. Modugno, S. Spinelli, F. Marsicano, M. Mistichelli, F. Marsicano, F. Giorgini, M. Verzella (Pozzilli, Italy)

12:00pm-1:30pm: Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm: Pallidal versus subthalamic stimulation for PD: Beyond the motor effects

M.G. dos Santos Ghilardi, R.G. Cury, R.C.R. Martinez, M.J. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:00pm-1:30pm: PARK-OMM – An osteopathic manipulative medicine protocol to improve motor function and balance in Parkinson’s disease

S. Yao, K. de Vries, J. DiFrancisco-Donoghue, J. Mancini, M.K. Jung, G. Cheriyan, S. Curtis, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm: Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC

A.E. Halpern, L.O. Ramig, K. Freeman, J.L. Spielman (Denver, CO, USA)

12:00pm-1:30pm: Pathological findings from two Parkinson’s disease patients after intraputaminal GDNF infusion

T.R. Yamasaki, V.D. Smith, Y. Ai, D.M. Gash, P.T. Nelson, G.A. Gerhardt, J.T. Slevin (Lexington, KY, USA)

12:00pm-1:30pm: Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias

S.J. Sherman, T. Falk (Tucson, AZ, USA)

12:00pm-1:30pm: PD COMM Pilot: A pilot randomised controlled trial of Lee Silverman voice treatment (LSVT) versus NHS speech and language therapy versus no intervention in Parkinson’s

C.M. Sackley, S. Patel, R. Woolley, N.J. Ives, C.E. Rick, F. Dowling, K. Wheatley, C. Smith, M. Brady, C.E. Clarke (London, United Kingdom)

12:00pm-1:30pm: PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

12:00pm-1:30pm: Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

12:00pm-1:30pm: Peripheral neuropathies in Parkinson’s disease during levodopa-carbidopa intestinal gel treatment: Results from a long-term prospective follow-up study

A. Romagnolo, A. Merola, M. Zibetti, A. Bernardini, D. Cocito, C.A. Artusi, F. Dematteis, S. Angrisano, M.G. Rizzone, L. Lopiano (Turin, Italy)

12:00pm-1:30pm: Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human

M. Nomoto, M. Nagai, N. Nishikawa, K. Yano, Y. Kagamiishi, M. Akisada, S. Saito, M. Yuba, T. Koyanagi, A. Takeda (Tohon Ehime, Japan)

12:00pm-1:30pm: Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?

E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva, F.K. Shermukhamedova (Taskent, Uzbekistan)

12:00pm-1:30pm: Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: Is it a ‘chemical’ DBS?

T. Falk, M.J. Bartlett, T. Ye, L.B. Lazarus, M.L. Heien, S.L. Cowen, S.J. Sherman (Tucson, AZ, USA)

12:00pm-1:30pm: Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

12:00pm-1:30pm: Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

12:00pm-1:30pm: Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

12:00pm-1:30pm: Proprioceptive training as a means to enhance sensorimotor function in Parkinson’s disease

N. Elangovan, P. Tuite, J. Konczak (Minneapolis, MN, USA)

12:00pm-1:30pm: Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial

W. Schrempf, M. Fauser, K. Otto, M. Wienecke, C. Ossig, S. Brown, A. Maass, M.D. Brandt, U. Schwanebeck, X. Graehlert, H. Reichmann, A. Storch (Dresden, Germany)

12:00pm-1:30pm: Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

12:00pm-1:30pm: Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

12:00pm-1:30pm: Recent result of indicative evaluation for deep brain stimulation of Parkinson’s disease patients

H. Saiki, S. Matsumoto (Osaka, Japan)

12:00pm-1:30pm: Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

12:00pm-1:30pm: Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study

Z. Zhang, M. Asgharnejad, H. Xue, E. Surmann, L. Bauer (Beijing, People's Republic of China)

12:00pm-1:30pm: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up

B.J. Snow, E. Mulroy, M. Simpson, L. Macdonald, A. Bok, K. Taylor, J. Han, K. Durbin (Auckland, New Zealand)

12:00pm-1:30pm: Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

12:00pm-1:30pm: Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

12:00pm-1:30pm: Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I

A. Santos, J. Ferreira, A. Lees, F. Stocchi, O. Rascol, N. Lopes, H. Gama, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm: Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

A.N. Taravari (Skopje, Macedonia)

12:00pm-1:30pm: Smell perception and judgement in PD patients: Results of a study designed, conducted, analysed and reported by PD patients

J. Stamford (London, United Kingdom)

12:00pm-1:30pm: Speech and voice range profile in patients with Parkinson’s disease with deep brain stimulation: Preliminary data

G.L.A. Diaféria, A.E. Dias, M.J. Carvalho, R. Cury, E.R. Barbosa, E.T. Fonoff (São Paulo, Brazil)

12:00pm-1:30pm: STN-DBS in Parkinson’s disease with early motor complications – A 10 year follow-up

J. Muellner, F. Pineau, D. Maltête, J.L. Houeto, M.L. Welter, S. Navarro, P. Cornu, C. Bernasconi, Y. Agid, M. Schuepbach (Bern, Switzerland)

12:00pm-1:30pm: Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

12:00pm-1:30pm: Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

12:00pm-1:30pm: Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

12:00pm-1:30pm: Supplement use in PD is associated with delayed initiation of dopaminergic therapy

L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

12:00pm-1:30pm: Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes

Y.O. Trufanov (Kyiv, Ukraine)

12:00pm-1:30pm: Taking specialist clinics into community nursing homes

T. Williams, S. Mahon, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

12:00pm-1:30pm: Tear fluid as potential biomarker for the diagnosis of Parkinson’s disease

M. Börger, S. Funke, F. Maaß, A. Fischbach, M. Bähr, F. Grus, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm: Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

12:00pm-1:30pm: The application of mobile health technology to increase physical activity in persons with Parkinson’s disease

T.D. Ellis, T.R. DeAngelis, K. Hendron, J.T. Cavanaugh, N. Sullivan, L. Goehring, C.A. Thomas, M. Saint-Hilaire, N.K. Latham (Boston, MA, USA)

12:00pm-1:30pm: The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report

R. González-Maldonado, R. González-Redondo, C.G. DiCaudo (Granada, Spain)

12:00pm-1:30pm: The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study

R. Loureiro, J. Domingos, D. Peralta, J. Dean, J. Ferreira (Lisbon, Portugal)

12:00pm-1:30pm: The correlation between dietary fiber, fluid intake and constipation in patients with Parkinson’s disease

N. Kawashima, A. Tabata, A. Kumon, K. Miyashita, A. Sato, H. Onuma, S. Nakamura, E. Horiuchi, K. Hasegawa (Fujisawa, Japan)

12:00pm-1:30pm: The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients

R. Krüger, P. Lingor, T. Doskas, J. Henselmans, E.H. Danielsen, O. de Fabregues, A. Stefani, S.C. Sensken, J.C. Parra Riaza, K. Onuk, A. Yegin (Tübingen, Germany)

12:00pm-1:30pm: The effect of Mozart piano sonata on Parkinsonian tremor, rigidity and bradykinesia

A. Shoeybi, N. Olfati (Mashhad, Islamic Republic of Iran)

12:00pm-1:30pm: The effect of walking speed on postural stability in Parkinson’s disease fallers

M.H. Cole, M. Sweeney, Z.J. Conway, T.D. Blackmore, P.A. Silburn (Virginia, Australia)

12:00pm-1:30pm: The efficacy of tremor detection and suppression device in intractable rest tremor in patients with Parkinson’s disease

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

12:00pm-1:30pm: The impact of STN DBS on kinetic tremor in Parkinson’s disease patients

S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Warsaw, Poland)

12:00pm-1:30pm: The influence of cerebellar transcranial direct current stimulation on skill acquisition in Parkinson’s disease

L. Lima de Albuquerque, K. Fischer, S. Jalene, M.R. Landers, B. Poston (Las Vegas, NV, USA)

12:00pm-1:30pm: The Luxembourg Parkinson’s study: Integrating the Lewy body composite risk score into a longitudinal study

M. Kerschenmeyer, P. Kolber, G. Hipp, K. Roomp, S.K. Mosch, A. Schweicher, L. Longhino, M. Falz, V.P. Satagopam, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schreiner, R. Krüger (Belval, Luxembourg)

12:00pm-1:30pm: The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

12:00pm-1:30pm: The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

12:00pm-1:30pm: The potential therapeutic effect of intranasal administration of stem cells in rotenone model of Parkinson’s disease in mice

M. El-Gamal, M. Salama, M. Sobh, M. Emam, A. Abdalla, A. Lotfy, D. Sabry, M. El-Qotb, M. Sobh (Mansoura, Egypt)

12:00pm-1:30pm: Therapeutic yoga improves balance and balance confidence in Parkinson’s disease

F. Revilla, K. Woschkolup, A.A. Walter, B.L. Hawkins, E. Urrea-Mendoza, A.A. Schmid, J. Park, J. Sharp, M. VanPuymbroeck (Greenville, SC, USA)

12:00pm-1:30pm: Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey

F. Gandor, A. Kühn, J. Müller, F. Klostermann, T. Müller, D. Gruber, A. Lipp, A. Kivi, D. Kübler, F. Ehlen, G. Ebersbach (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm: Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease

M. Memedi, S. Aghanavesi, D. Nyholm, H. Askmark, S.M. Aquilonius, R. Constantinescu, F. Bergquist, A. Medvedev, A. Ericsson, F. Ohlsson, S. Lycke, J. Spira, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm: Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease

J. DiFrancisco-Donoghue, A. Leder, M.K. Jung, W.G. Werner (Old Westbury, NY, USA)

12:00pm-1:30pm: Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine

P. Sanchez-Lozano, E. Suarez, R. Ribacoba (Gijon, Spain)

12:00pm-1:30pm: Utilization and longitudinal impact of amantadine use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, T. Simuni, K. Li, S. Luo (Chicago, IL, USA)

12:00pm-1:30pm: Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, K. Li, S. Luo, T. Simuni (Chicago, IL, USA)

12:00pm-1:30pm: Validity and reliability of the test d evaluation des membres superieurs de personnes agees (TEMPA) to assess upper limb in Parkinson’s disease

C.L. Correa, P.R. de-Freitas, A.E. Lemos, S.M. Michaelsen, A. Swarowsky (Rio de Janeiro, Brazil)

12:00pm-1:30pm: VANTAGE trial: Three year outcomes of a prospective, multi-center trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

L. Timmerman, R. Jain, L. Chen, T. Brucke, F. Seijo, E. Suarez San Martin, C. Haegelen, M. Verin, V. Visser-Vandewalle, M.T. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

12:00pm-1:30pm: Virtual rehabilitation: A therapy for parkinsonism?

B.S. Zeigelboim, G.J.B. Santos, M.I.R. Severiano, H.A.G. Teive, A.B.M. Lacerda, C.M. Porto (Curitiba, Brazil)

12:00pm-1:30pm: Virtual-reality balance training with Nintendo-Wii games improves dynamic balance in Parkinson’s disease patients

G.H. Lee (Cheon-An, Korea)

12:00pm-1:30pm: Voice harmonic amplitude differences before and after LSVT LOUD^TM in Parkinson’s disease

M.P. Cannito, L.O. Ramig, A.E. Halpern, J.L. Spielman (Lafayette, LA, USA)

12:00pm-1:30pm: When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm: Whole body vibration therapy with exercise enhances motor function and improves quality of life in Parkinson’s disease

O.K. Gruder, D.Y. Edmonston, G.Q. Barr, C.G. Maitland (Tallahassee, FL, USA)

« View all sessions from the 20th International Congress.